Geeez well the R&D Tax Rebate definately saved a bit of ass
90& decrease in revenue just $134K VS $1.38M previous year
While i understand progress being made with current partnerships & internally i still get a bit concerned with ability to secure new deals ? I think the whole "big pharma restructuring" line is wearing pretty thin, they certainly haven't slowed securing deals elsewhere and that lines been used for ? 18 months now ? Don't forget these deals have miniscule upfronts so i struggle to see why it's so difficult for multi billion dollar pharmaceutical companies if they see the potential .
Also for deals that have repeatedly sounded like they were on the verge time moves & not much changes. How do deals that where repeatedly believed to be on the cusp of formalising continue to strectch like this ? they where confident of the 2 before end of 2012 right up until end of year but it now still sounds some time away in this report - multiple discussions are underway, "including some at relatively advanced stages." -------- now just "relatively" ? PS i don't really care about "multiple" at the moment - i'd just like 1 :-)
Sound likes a bit of a whingey post & sorry to sound a bit downbeat - but i'm sure i'm not the only one ?
PYC Price at posting:
2.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)